Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

• Main Authors: JungJin Oh (Author), Eunsol Yang (Author), In-Jin Jang (Author), Hyejung Lee (Author), Hokyun Yoo (Author), Jae-Yong Chung (Author), SeungHwan Lee (Author), Jaeseong Oh (Author)
• Format: Book
• Published: MDPI AG, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal complications. This randomized, open-label study aimed...